Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $51.26 and last traded at $51.26, with a volume of 0 shares changing hands. The stock had previously closed at $51.26.
Analyst Upgrades and Downgrades
Separately, HC Wainwright raised Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.
Get Our Latest Stock Report on Basilea Pharmaceutica
Basilea Pharmaceutica Stock Performance
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Read More
- Five stocks we like better than Basilea Pharmaceutica
- The 3 Best Retail Stocks to Shop for in August
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- How Can Investors Benefit From After-Hours Trading
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- What is the Dow Jones Industrial Average (DJIA)?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
